ACCESS CHINA Biotech Forum


Effective partnering and China market assessment platformACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.

Who should present?

Global pharma/biotech companies:

  • Looking for out-licensing opportunities in China
  • With clinical-stage assets
  • Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, and GI areas

Chinese pharma/biotech companies

  • Looking for out-licensing opportunities in China or worldwide
  • Looking for equity investment opportunities in China
  • Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, and GI areas

Who are the attendees ?

  • BD and c-level people from Chinese pharma/biotechs looking for in-licensing opportunities to enrich pipeline (Global out-licensing session and domestic out-licensing session)
  • BD and c-level people from ex-China pharma/biotechs looking for in-licensing opportunities to enrich pipeline in China and other regions (Global out-licensing session and China cross-border out-licensing session)
  • Chinese funds looking for pharma/biotech investment opportunities (China domestic fundraising session)

Why China ?

In/out-licensing is becoming the major business strategy among Chinese pharma.

China related licensing transactions greatly increased despite of COVID-19 in 2020. There were total 129 China related cross border licensing deals including 36 out-licensing deals and 93 in-licensing deals, representing an increase of 59% y/y. Most notably, out-licensing deals reached 36 in 2020, versus 6 in 2019.

Why ACCESS CHINA?

1.Broader Chinese strategic investors coverage

Compare to other conferences like Bio Convention and BioEurope, ACCESS CHINA has the broadest coverage of Chinese strategic investors that are looking for in-licensing opportunities.

2.Quicker China market assessment

We gather interests for presenters 1 week after the company presentations which allows the presenter to assess the level of interest in China market very quickly.

3.More exposure

ACCESS CHINA promotes presenting companies through various means including asset listing on platform, video roadshow on live day and on demand, asset report distribution to AC members, and promoting to targeted investors through emailing and Wechat articles (for paid clients only).


Upcoming Events

ACCESS CHINA Biotech Forum is a quarterly corporate access event series between China and Western biopharma. It is a leading deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market, and for Chinese companies to enter the global market.

ACCESS CHINA – 2021 Autumn Showcase

ACCESS CHINA Biotech Forum @ The 16th China Pharma and Medtech BD Summit

September 23rd-24th, 2021, Suzhou and Online The largest China oriented healthcare partnering event – We are honored to invite you to our “ACCESS CHINA @The Sixteenth China Pharmaceutical and Medtech Business Development Summit”, which will take place on September 23rd-24th, 2021. This conference is the largest China oriented corporate access event with 100+ company presentations,…

Keep reading

Past Events

ACCESS CHINA is a series of events that YAFO organizes each year, including East Meets West Mixing Dinner @ JPM, ACCESS CHINA BD Forum @ BIO International Convention, CHINA BD Forum (September each year), and ACCESS CHINA Online Partnering. During 2020 we’ve helped 333 companies presented their products in front of global pharma and investment firms.

333

companies

16500+

views

2800+

requests

600+

assets


Licensing Opportunities Report